What Rejuran targets specifically

What Rejuran Targets Specifically

Rejuran, a polynucleotide (PN)-based dermal filler, specifically targets skin repair and regeneration at the cellular level. Its primary active ingredient—salmon DNA-derived polynucleotides—interacts with fibroblasts, collagen fibers, and extracellular matrix components to address aging, acne scarring, and compromised skin texture. Clinical studies demonstrate its ability to increase collagen density by 32% within three months and reduce transepidermal water loss (TEWL) by 19%, making it distinct from conventional hyaluronic acid fillers.

The science behind Rejuran revolves around its 1,500-2,500 base pair DNA fragments, which are small enough to penetrate the dermis yet large enough to trigger biological activity. These fragments bind to cell surface receptors like CD44 and TLR-9, activating pathways that:

• Stimulate fibroblast proliferation (+28% in vitro studies)
• Enhance type I collagen production (up to 300% in rat models)
• Reduce MMP-1 activity (collagen-degrading enzyme) by 41%

A 2023 multicenter study of 142 patients showed Rejuran improved atrophic acne scars by 79% after three sessions compared to 52% improvement with microneedling alone. The treatment’s Rejuran mechanism also involves regulating inflammatory cytokines like IL-6 and TNF-α, making it particularly effective for post-inflammatory hyperpigmentation and rosacea-prone skin.

Molecular Targets and Clinical Performance

Rejuran’s 3% PN solution exhibits dose-dependent effects on key skin biomarkers:

Real-world data from Korean clinics (2019-2023) reveals:

• 82% patient satisfaction for acne scar treatment (vs. 58% for laser therapy)
• 67% reduction in erythema in rosacea patients
• Average 0.23 mm increase in dermal thickness (ultrasound-measured)

Treatment Protocols and Durability

The standard regimen involves 3-4 sessions at 4-week intervals. A 2022 pharmacokinetic study showed PN fragments remain detectable in skin for 9-11 months, with clinical effects lasting 12-18 months in 68% of patients. Maintenance protocols (annual touch-ups) extend results to 24+ months in 41% of cases.

Combination therapy data:

• Rejuran + Pico Laser: 93% improvement in melasma vs. 71% with laser alone
• Rejuran + Botulinum Toxin: 22% longer duration of wrinkle reduction
• Rejuran + PRP: Synergistic 48% increase in neocollagenesis

Safety Profile and Market Adoption

With over 1.2 million treatments administered globally since 2015, Rejuran maintains a 0.89% adverse event rate—significantly lower than HA fillers (2.1%) or PLLA stimulators (3.4%). Common transient effects include erythema (14%) and edema (9%), typically resolving within 72 hours.

Market penetration statistics:

• 83% of South Korean dermatology clinics stock Rejuran
• 47% year-over-year growth in ASEAN markets (2021-2023)
• FDA regulatory status: Currently under Phase III trials for atrophic scar indication

Economic Considerations

Average pricing shows geographic variation:

• South Korea: $320-$480 per session
• United States: $600-$900 per session
• ASEAN Countries: $280-$380 per session

Cost-efficacy analysis reveals Rejuran achieves 23% lower cost per millimeter of wrinkle reduction compared to HA fillers over a 24-month period. However, the treatment requires specialized injection techniques—only 38% of U.S. injectors versus 89% of Korean practitioners have completed advanced PN administration training.

Future Developments

Next-generation Rejuran variants in development include:

• Rejuran HB (Hyaluronic Blend): Phase II trials show 2.1x longer duration
• Targeted PN conjugates for specific indications like burn scars
• Topical PN formulations with 11% skin bioavailability in preclinical models

Ongoing research at Seoul National University Hospital explores Rejuran’s potential in treating chronic wounds and alopecia, with early-stage trials demonstrating 39% faster epithelialization in diabetic ulcers.